About Oxular
Oxular is a company based in Oxford (United Kingdom) founded in 2014 was acquired by Regeneron Pharmaceuticals in January 2025. Oxular has raised $57.53 million across 2 funding rounds from investors including Regeneron Pharmaceuticals, IP Group and Hovione. The company has 6 employees as of September 30, 2021. Oxular operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
- Headquarter Oxford, United Kingdom
- Employees 6 as on 30 Sep, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oxular Limited
- Date of Incorporation 27 Nov, 2014
- Jurisdiction OXFORD, ENGLAND
-
Annual Revenue
$2.1 M (USD)1348as on Oct 31, 2022
-
Net Profit
-$16.87 M (USD)-115as on Oct 31, 2022
-
EBITDA
-$21.01 M (USD)-119as on Oct 31, 2022
-
Total Equity Funding
$57.53 M (USD)
in 2 rounds
-
Latest Funding Round
$37 M (USD), Series B
Mar 01, 2021
-
Investors
Regeneron Pharmaceuticals
& 7 more
-
Employee Count
6
as on Sep 30, 2021
-
Acquired by
Regeneron Pharmaceuticals
(Jan 02, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Oxular
Unlock access to complete
Unlock access to complete
Leadership Team
10 people
Operations Team
1 people
Finance and Accounting
1 people
Observer Team
1 people
Unlock access to complete
Funding Insights of Oxular
Oxular has successfully raised a total of $57.53M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $37 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Oxular
Oxular has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Regeneron Pharmaceuticals, IP Group and Hovione.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on lifescience and healthcare sectors
|
Locked | Locked | Locked | |
|
Venture capital and advisory services are offered across multiple sectors.
|
Locked | Locked | Locked | |
|
V-Bio Ventures is engaged in life science venture capital investment.
|
Locked | Locked | Locked |
Investor details for Oxular
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oxular
Investment portfolio details for Oxular
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Oxular
Detailed financials for Oxular
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oxular Comparisons
Peer comparison for Oxular
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oxular
Oxular operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
Detailed competitors of Oxular
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oxular
Complete news archive for Oxular
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oxular
Oxular was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Oxular is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Oxular is a funded company, having raised a total of $57.53M across 2 funding rounds to date.
As of Sep 30, 2021, the latest employee count at Oxular is 6.
Annual revenue of Oxular is $2.1M as on Oct 31, 2022.
Founded in 2014 in Oxford, United Kingdom, operations center on the development of drug delivery platforms and therapeutics within the ophthalmology sector. Key programs, including OXU-001 and OXU-003, facilitate targeted drug delivery to posterior ocular tissues. The Oxusphere, a biodegradable polymer system containing drugs, is utilized alongside the Oxulumis, a semi-automated ocular administration device. Indications such as age-related macular degeneration, diabetic macular edema, and rare ophthalmic disorders are being explored.
Oxular's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Oxular has 8 investors. Key investors include Regeneron Pharmaceuticals, IP Group, Hovione, Consort Medical, and Imperial Innovations.